ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 866

Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy

Chio Yokose1, Yuqing Zhang2, Nicola Dalbeth3, Jie Wei1, Savvas Nicolaou4, Scott Baumgartner5, Jia Hu6, Maple Fung5 and Hyon K. Choi1, 1Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, 2Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 3University of Auckland, Auckland, New Zealand, 4Radiology, University of British Columbia, Vancouver, BC, Canada, 5Formerly Ardea Biosciences, San Diego, CA, 6Heron Therapeutics, San Diego, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: crystal-induced arthritis and gout, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Gout is typically characterized as an acute monoarthritis involving the joints of the foot. However, polyarticular involvement develops, especially in advanced disease. Patterns of involvement of monosodium urate (MSU) crystal deposition such as symmetry and clustering in patients with gout has never been described. The aim of this study was to evaluate patterns of MSU deposition using dual-energy CT (DECT) among gout patients on urate-lowering therapy (ULT).

Methods:

Using standardized acquisition protocols, DECT scans of the feet/ankles, knees, and hands/wrists were prospectively obtained in 153 patients with a known diagnosis of gout (all meeting 1977 ARA gout classification criteria) and on allopurinol at a dose of at least 300mg daily for at least 3 months. MSU deposition was evaluated by 2 DECT radiologists at 12 sub-sites in the feet/ankles, 4 sub-sites in the knees, and 15 sub-sites in the hands/wrists. We calculated the number of subjects who would have 0, 1, 2, 3, 4, or 5+ joints with MSU deposition, assuming that its presence in different joints in a subject is independent. Clustering of MSU deposition in the 3 regions was assessed using a χ2-test. We then evaluated the patterns of MSU deposition at different joints with generalized estimating equations while adjusting for age, sex, and race.

Results:

Our analysis included 153 patients (92% male) with gout (mean disease duration, 15 years) on allopurinol (mean duration of therapy, 5 years; mean daily dose, 333mg). MSU deposition was observed in a clustered manner at multiple joints of the hands/wrists, feet/ankles, and knees more frequently than would be expected by chance (p<0.001 for all 3 regions). Presence of MSU deposition at a given joint was strongly associated with MSU deposition at the same joint of the opposite extremity (i.e., symmetric involvement), followed by other joints in the same ray of the hand or foot (i.e., multiple joints of one digit), followed by other joints in the same row of the hand or foot (i.e., same joint across multiple digits).

Conclusion:

MSU deposition often affects multiple joints of the feet/ankles, knees, and hands/wrists in a clustered manner. MSU deposition tends to occur in a highly symmetric pattern in all three regions evaluated. In the hands and feet, MSU deposition is more likely to cluster by ray (i.e., multiple joints of one digit) than by row (i.e., same joint across multiple digits). These findings may shed light on pathophysiologic factors that lead to MSU deposition and may inform clinicians’ decisions to obtain bilateral vs unilateral imaging of a target joint.

Table 1 – Pattern of MSU Deposition in Treated Patients with Gout

 

Adjusted Odds Ratio* (95% CI)

Hand

 

Same joint, other side

26.1 (2.6, 263.6)

Same ray, same side

15.0 (2.1, 107.8)

Same row, same side

14.9 (1.9, 114.3)

Foot

 

Same joint, other side

46.9 (23.9, 92.2)

Same ray, same side

4.6 (2.0, 10.6)

Same row, same side

1.5 (0.7, 3.1)

Knee

 

Same joint, other side

9.9 (5.9, 16.5)

Same row, same side

4.2 (2.5, 7.2)

*Adjusted for other joints, age, sex and race.

 


Disclosure: C. Yokose, None; Y. Zhang, None; N. Dalbeth, Horizon, 5,Kowa, 5,Amgen Inc., 2,AstraZeneca/Ironwood, 2,AbbVie Inc., 8,Pfizer, Inc., 8,Janssen, 8; J. Wei, None; S. Nicolaou, Siemens, 9; S. Baumgartner, Ardea Biosciences, 3; J. Hu, Heron Therapeutics, 3; M. Fung, Ardea Biosciences, 3; H. K. Choi, Takeda, Selecta, Kowa, and Horizon, 5,Selecta and Horizon, 2.

To cite this abstract in AMA style:

Yokose C, Zhang Y, Dalbeth N, Wei J, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK. Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/patterns-of-monosodium-urate-deposition-on-dual-energy-ct-in-gout-patients-on-urate-lowering-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-monosodium-urate-deposition-on-dual-energy-ct-in-gout-patients-on-urate-lowering-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology